Print ISSN: 2394-6369
Online ISSN: 2394-6377
CODEN : IJCBK6
International Journal of Clinical Biochemistry and Research (IJCBR) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award more...Case Series
Author Details :
Volume : 11, Issue : 3, Year : 2024
Article Page : 198-203
https://doi.org/10.18231/j.ijcbr.2024.029
Abstract
Hypercholesterolemia is one of the main modifiable risk factors for the onset of myocardial infarction, and one of the key factors for the onset of hypercholesterolemia is the genetic predisposition. The therapy of choice to restore cholesterol to normal values is represented by statins, a class of cholesterol biosynthesis inhibitors. Some patients are intolerant to this class of molecules, triggering serious side effects, or show a resistance (often based also on genetic factors) to their action. In this report we present the case of two related patients (mother and son) with familial hypercholesterolemia of medium severity. The first patient presents total resistance to all the statins tested (simvastatin, monacolin K, rosuvastatin) at any dosage and the resolution is found by combining the rosuvastatin therapy with ezetimibe, an inhibitor of intestinal cholesterol absorption. For the second patient, in therapy with a supplement of monacolin K, the feedback is positive even at low doses.
Keywords: Ccholesterol, LDL, Ffamiliar hypercholesterolemia, Sstatins, Mmonacolin K, Ffermented red rice, Rrosuvastatin, Eezetimibe
How to cite : Achilli C, Gasparri C, Moroni A, Nondanevi M, A double case study. Mother, son, and their familial dyslipidemia: A different response to statin treatment. Int J Clin Biochem Res 2024;11(3):198-203
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.